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Abstract
Background: In addition to surfactant deficiency, increase of lung fluid content and secretion of fluid derived from
the blood participate in the pathogenesis of RDS in newborns.
We hypothesized that the administration of salbutamol (β-agonist) to increase lung fluid absorption would decrease
the INSURE failure rate in newborns with respiratory distress syndrome (RDS) treated with intratracheal surfactant.
Methods:
Design
Blinded, randomized clinical trial study.
Setting/population
Level III NICU, premature infants with RDS requiring intratracheal Surfactant.
Forty Eight newborns with RDS treated with intratracheal Surfactant were randomized into two groups as Group A,
Normal saline (as control group) and Group B (intervention group), Salbutamol were administered intratracheally in
addition to Surfactant. Intubation-Surfactant administration- Rapid Extubation (INSURE) failure rate as primary outcome
and secondary outcome as follow: duration of the need to NCPAP, mechanical ventilation and oxygen therapy;
complications (patent ductus arteriosus, pneumothorax); mortality (respiratory or prematurity related complication) and
the duration of hospitalization were assessed.
Results: Twenty Four patients in each group were studied. INSURE failure was seen in16 (66.7 %) and 10 (41.7 %) of
normal saline and salbutamol groups respectively (p = 0.082). The duration of NCPAP in control group was 69.5 ± 54.9 h
while in Salbutamol group was 51.6 ± 48.7 h (p = 0.316). All of deaths were related to respiratory failure. No differences
in mortality or complications of RDS were observed. The duration of hospitalization was longer in control group than
interventional group, 28.3 ± 18.1 and 18.6 ± 8.6 days, respectively. (p = 0.047).
Conclusion: Salbutamol may improve the clinical course of newborns with RDS requiring Surfactant.
Trial registration number: IRCT2014072714215N1
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Background
Respiratory distress syndrome (RDS) is one of the most
common causes of neonatal respiratory failure and neo-
natal mortality. The risk of developing RDS increases
with decreasing gestational age. Immaturity of the lungs
and, specifically, surfactant deficiency are the corner-
stone of RDS in newborns [1]. In addition to Surfactant
deficiency, increase of lung fluid content and secretion
of fluid derived from the blood participate in the patho-
genesis of RDS in newborns [2]. During the last gesta-
tion period, the fetal lung airways contain 40 ml/kg fluid
which is somewhat greater than the Functional residual
capacity [3]. Active transport of chloride ion from the
plasma into the pulmonary alveolar spaces creates an
electrical potential difference of 4.3 mV between lung li-
quid and plasma [4]. The osmotic force that is generated
by this secretion process results in the transport of fluid
from pulmonary microcirculation and interstitial fluid
into alveolar spaces. Active transport of clˉ from plasma
into alveolar spaces is probably mediated via Na-K-2Cl
(NKCC) co-transporters [5].
Transport of clˉ that begins in mid-gestation is inhibited
by loop diuretics such as Furosemide that block NKCC
co-transporters [6].
Labor process has an important role in lung airways
fluid absorption and preparation for air respiration. Dur-
ing vaginal delivery, a lot of lung fluid propelled from
the airways and mouth, but the active transport of
sodium mediated via Na+/K+-ATPase channel is the
basic mechanism for the clearance of fetal lung airways
[7–10]. Several investigators have shown that high en-
dogenous catecholamine secretion at birth is an im-
portant factor in fetal lung clearance by the induction
of Na+/K+-ATPase pump [11, 12]. In addition, it has
been shown that β-agonists increase the Na channel
activity mediated by cAMP-PKA and lung sodium
transport [13]. Secretion of liquid into the trachea of
the fetal lambs begins to decrease a few days before
spontaneous vaginal delivery [14]. Very premature infants
have immature lungs that are surfactant deficient, partially
liquid filled, and prone to atelectasis at end expiration [15].
Mechanical ventilation (MV) and nasal continuous
positive airway pressure (NCPAP) are the most respiratory
support techniques that used in treatment of newborns
with RDS [16]. Intubation-Surfactant administration- Rapid
Extubation (INSURE) is associated with less need to mech-
anical ventilation, lower incidence of BPD and fewer air
leak syndromes [17]. Although this method has been
clearly associated with reduced need for MV [18] not
all infants can be successfully managed with this mo-
dality. INSURE failure has been registered in 27 to
35.6 % [19, 20].
Our objective in this study was to assess the effects of
Salbutamol in order to increase fluid absorption from
the alveoli and reduction of INSURE failure in prema-
ture newborns with RDS.
Methods
This clinical trial study with registration number
IRCT2014072714215N1 was performed at Neonatal in-
tensive care Unit of Imam Khomeini Hospital, Ahvaz
Jundishapur University of Medical Sciences, Ahvaz,
IRAN, a teaching tertiary care center with 36 and 45
beds of level 3 and 2 respectively. Initially as a pilot
study, 10 newborns with respiratory distress syndrome
who needs intratracheal surfactant beside NCPAP man-
agement were randomly assigned to receive surfactant
plus normal saline or surfactant plus salbutamol. The
sample size was calculated based on our primary out-
come (insure failure), p1: 0.4, p2: 0.08, considering 80 %
as the power of the study, and confidence interval 95 %.
As the results, 24 patients in each group were enrolled
in this study.
Newborns at our hospital with gestational age less
than 34-o/7 weeks and birth weight greater than 1000 g.,
with a diagnosis of RDS according to clinical and radio-
graphic findings and negative blood culture were eligible
for inclusion in this study. Because of high mortality rate
of newborns with birth weight less than 1000 g. in our
institute, they did not included in this study. The clinical
signs and symptoms of RDS were respiratory distress,
tachypnea, nasal flaring and grunting after birth. The
typical chest x- ray picture of RDS showed a grainy
shadow, air bronchogram, and white lung. Newborns
with birth trauma, congenital anomalies, and perinatal
asphyxia, 5 min apgar score ≤ 3, negative radiologic find-
ing, severe metabolic acidosis at birth and positive blood
culture were excluded. Patients were hospitalized at our
neonatal intensive care unit from March 21, 2014, through
July 11, 2014. An informed consent was obtained from pa-
tients’ parents. Newborns diagnosed with RDS and birth
body weight greater or lesser than 1500 g were treated
with oxyhood or nasal continuous positive airway pressure
(NCPAP) [21]. Arterial Blood Gases (ABG) was measured
30 min later. Neonate with ABG (Pao2: 50–70 mmHg,
pH: 7.25- 7.45, Paco2: 40–50 mmHg) were observed
closely. Under NCPAP neonates with ABG (pH 7.3- 7.45,
Paco2 40–50 mmHg, Pao2 < 50 mmHg) while received
6 cm H2o PEEP and needed greater than 40 % Fio2 were
treated with intratracheal surfactant [20]. NCPAP were
discontinued in infants with favorable ABG when received
4 cm H2o PEEP and Fio2 lesser than 40 % without
increasing work of breathing, no substantial apnea
and bradycardia [22].
Surfactant was administered to the infants base on
INSURE protocol within 2 h of birth. Curosurf (Cheisi
farmaceutici S.P.A) with initial dose of 2.5 ml/kg and
subsequent doses of 1.5 ml/kg were used [23]. Patients
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who required to Fio2 greater than 0.3 were treated with
repeated doses of surfactant.
The neonates treated with Surfactant and Normal sa-
line (control group) or Salbutamol (interventional group)
base on the computerized randomization list. In addition
to Curosurf, the doses were used as follows: intratracheal
Normal saline of 0.5 ml/kg or intratracheal Salbutamol of
0.2 mg/kg [24]. Solution containing Salbutamol 0.4 mg/ml
was prepared with clinical pharmacist. Normal saline was
used for the dilution of Salbutamol and preparation of
suitable volumes. Therefore, in each patient group, a vol-
ume equal to 0.5 ml/kg of Normal saline or prepared solu-
tion was administered in addition to Surfactant. Normal
saline or Salbutamol was administered immediately after
administration of Surfactant via the same intratracheal
tube. In each patient, if additional doses of Surfactant were
needed, the same solution was used again. Solution vials
containing Normal saline and Salbutamol were labelled
with A and B, respectively. Echcardigraphy was performed
in newborns patient with hyperkinetic heart, murmur,
binding pulses and increased need to respiratory support
after third days of life. The physician and caretaker
were blinded to vial content, and the patients were
enrolled in the study according to the table of com-
puterized randomization list.
Primary and secondary outcomes
The primary outcome was INSURE failure. INSURE failure
was defined as the need for reintubation and MV within
72 h of extubation. Mechanical ventilation was considered
Fig. 1 Participant CONSORT flow diagram: approach to neonates with respiratory distress syndrome treated with intratracheal surfactant and
salbutamol or only surfactant
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in babies with PaO2 < 50 mmHg or PaCO2 > 55 mmHg
and pH < 7.25 with FiO2 > 0.4 and PEEP > 6 cm H2o; or
those with increasing work of breathing including severe
intercostal retractions on PEEP >7 cm H2o; or prolonged
(>20 s) or recurrent apneas and bradycardia (>2 episodes
within 24 h) need to bag and mask ventilation [25, 26].
Ventilated newborns with suitable ABG (Pao2 60–
80 mmHg, Paco2 40–55 mmHg and pH 7.25- 7.45) and
without increasing work of breathing were moved to
NCPAP when they received a low PIP (10–12 cm H2o),
Fio2 lesser than 40 %, and respiratory rate of 10- 15/min
[27]. The secondary outcomes; duration of the need to
NCPAP, Mechanical Ventilation, oxygen and also mortality
(respiratory or prematurity related complication), morbid-
ity (patent ductus arteriosus, pneumothorax) and discharge
from hospital were assessed. Full oral feeding (150 ml/kg/
day) and starting to weight gain was the discharge criteria.
Statistical analysis
Comparison between continuous and independent vari-
ables was performed using Mann–Whitney, and chi-square
test. All the statistical analysis was performed using SPSS
version 16 (IBM, Armonk, New york). p Value <0.05 was
considered significant.
Results
Of the 50 patients enrolled in this study, one patient in
control group and another in Salbutamol group were
excluded from the study when diagnosed with perinatal
asphyxia and congenital heart disease (Fig. 1).
Demographic data of studied patients have been shown
in Table 1. Tachycardia (heart rate > 160/min) was not
seen in any neonate treated with salbutamol.
NCPAP failure rate and the need for mechanical venti-
lation were greater in control group (Table 2). There was
no significant difference for Patent Ductus Arteriosus
between two groups (p =1). Pneumothorax was seen in
two patients of control group, but not detected in any
neonates of salbutamol group (p = 0.149). The duration
of hospitalization was shorter in interventional group
than control group,18.63 ± 8.62 and 28.31 ± 18.17 days,
respectively (p = 0.047). Respiratory failure was the cause
of death in all of the expired infants. The mortality rate
was greater in control group [8(33.3 %) VS 5(20.8 %)];
however, these differences between interventional and
control groups was not significant (p = 0.330).
Discussion
The primary aim of this study was to assess whether the
increase of absorption of lung fluid by administering
Salbutamol in addition to Surfactant, could affect the
clinical course of neonates with RDS. This study showed
that newborns with RDS who were treated with intratra-
cheal Salbutamol, accompanied by Surfactant had a lesser
degree of NCPAP failure and the need for mechanical
ventilation. Also the duration of NCPAP, mechanical ven-
tilation and oxygen therapy were shorter in interventional
group than the control group.
However this diffrencess were not significant, that may
be related to low number of our population study groups.
Since the demographic characteristics of newborns in
interventional and control groups were not different these
findings were probably related to the use of Salbutamol
accompanied by Surfactant in the treatment of newborns
with RDS. A previous study showed that β-agonists, be-
sides decreasing lung fluid, played a great role in improv-
ing arterial blood gases [28]. Lung fluid absorption is
primarily the effect of active Na + transport across the pul-
monary epithelium derived from lung air spaces to the in-
terstitium. Intra alveolar Na + extracted from airspaces to
the interstitium through activation of Na+/K + −ATPase.
Βeta-agonists can induce Na+/K + −ATPase pump [29].
Sakumaet al. have shown that β-agonists induce cAMP
and subsequently increase lung fluid clearance [30].
Table 1 Patients’ demographic characteristics
Variable Surfactant with
N.S. (n = 24)
Surfactant with
Salb. (n = 24)
p
G. age (week) 29.70 ± 2.27 30.04 ± 2.07 0.59
B.B.W (g) 1430.83 ± 393.41 1443 ± 267.22 0.89
Gender
M. 15(62.5 %) 17(70.8 %) 0.54
F. 9(37.5 %) 7(29.2 %)
Delivery
C.S. 18(75 %) 19(79.2 %) 0.73
Vag. 6(25 %) 5(20.8 %)
Perenatal steroid
Yes 11(45.8 %) 10(41.7 %) 0.77
No 13(54.2 %) 14(58.3 %)
Curosurf dosage
1 20(83.3 %) 18(75 %) 0.47
2 4(16.7 %) 6(25 %)
N.S normal saline, Salb salbutamol, G gestational, B.B.W birth body weight,
M male, F female, C.S cesarean section, Vag vaginal
Table 2 Comparison of INSURE failure (need for Mechanical
Ventilation), the duration of NCPAP, the Mechanical Ventilation
(M.V.) and oxygen requirement between control and interventional
groups
Variable Surfactant with
N.S. (n = 24)
Surfactant with
Salb. (n = 24)
p
INSURE Failure n(%) 16(66.7 %) 10(41.7 %) 0.082
Duration of NCPAP (h) 69.50 ± 54.97 51.63 ± 48.77 0.316
Duration of M.V. (h) 38.12 ± 80.67 9.73 ± 18.57 0.145
Duration of oxygen therapy(h) 93.56 ± 134.77 60.21 ± 41.88 0.313
N.S normal saline, Salb salbutamol, M.V mechanical ventilation
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There was one case with patent ductus arteriosus in con-
trol group, that was not significantly difference between
two groups. The duration of hospitalization was less in
interventional groups compared with the control group. A
shorter duration of NCPAP or the mechanical ventilation
and early feeding of these neonates may be associated with
earlier discharge of neonates in interventional groups. In
our study, however, the mortality rate was not significantly
different between interventional and control groups, but
the mortality rate in control group was greater than the
salbutamol group. Because of the underdevelopment of
the intensive care for extremely low birth weight (ELBW)
in our institute, we did not enroll newborns with ELBW
in our study; thus, it is a great limitation of our study.
Conclusion
According to the result of this study, intratracheal admin-
istration of β-adrenergic (Salbutamol) accompanied by
Surfactant can decrease the duration of NCPAP, NCPAP
failure rate and reduce the need for mechanical ventilation
in newborns with RDS.
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